Potential of solid dispersions to enhance solubility, bioavailability, and therapeutic efficacy of poorly water-soluble drugs: newer formulation techniques, current marketed scenario and patents
In the last few decades, solid dispersion (SD) technology had been studied as an approach to produce an amorphous carrier to enhance the solubility, dissolution rate, and bioavailability of poorly water-soluble drugs. The use of suitable carrier and methodology in the preparation of SDs play a significant role in the biological behavior of the SDs. SDs have been prepared using a variety of pharmaceutically acceptable polymers utilizing various novel technologies. In the recent years, much attention has been paid toward the use of novel carriers and methodologies in exploring novel types of SDs to enhance therapeutic efficacy and bioavailability. The use of novel carriers and methodologies would be very beneficial for formulation scientists to develop some SDs-based formulations for their commercial use and clinical applications. In the present review, current literature of novel methodologies for SD preparation to enhance the dissolution rate, solubility, therapeutic efficacy, and bioavailability of poorly water-soluble drugs has been summarized and analyzed. Further, the current status of SDs, patent status, and future prospects have also been discussed.
Download the full article here: Potential of solid dispersions to enhance solubility bioavailability and therapeutic efficacy of poorly water soluble drugs newer formulation
or continue reading here: Sultan Alshehri , Syed Sarim Imam , Afzal Hussain , Mohammad A. Altamimi , Nabil K. Alruwaili , Fahad Alotaibi , Abdullah Alanazi & Faiyaz Shakeel (2020) Potential of solid dispersions to enhance solubility, bioavailability, and therapeutic efficacy of poorly water-soluble drugs: newer formulation techniques, current marketed scenario and patents, Drug Delivery, 27:1, 1625-1643, DOI: 10.1080/10717544.2020.1846638
Some further insights of this article
| Drug | Carrier | Method |
|---|---|---|
| Nifedipine, efavirenz | Hydroxypropyl methylcellulose acetate succinate | Hot melt extrusion |
| Mefenamic acid | EudragitVR EPO | Hot melt extrusion |
| Mefenamic acid | Kollidon® 12 PF and 17 PF | Hot melt extrusion |
| Carbamazepine | Soluplus® | Hot melt extrusion |
| Piperine | Eudragit® EPO, Kollidon® VA 64, Soluplus® | Hot melt extrusion |
| Lansoprazole | Kollidon® 12 PF, Lutrol® F 68, MgO | Hot melt extrusion |
| Aripiprazole | Kollidon® 12 PF (PVP) and succinic acid | Hot-melt extrusion |
| Hydrocortisone | Polyethylene glycol 4000 (PEG 4000), Kolliphor® P 407 | Spray drying |
| Apigenin | Pluronic-F127 | Microwave irradiation |
| Mefenamic acid and flufenamic acid | Pluronic F127® (PL), Eudragit EPO® (EPO), polyethylene glycol 4000 (PEG 4000), Gelucire 50/13 (GLU) | Microwave irradiation |
| Nifedipine, sulfamethoxazole | Soluplus®, PEG 6000 | Spray drying, lyophilization |
| Efavirenz | href="https://www.pharmaexcipients.com/product/soluplus/">Soluplus® | Spray-drying |
| Apigenin | Pluronic F 127 | Spray drying |
| Sirolimus | Eudragit® E HPMC | Spray drying |